Carregant...
Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
BACKGROUND: In this study, we analyze the cost-effectiveness of fruquintinib as third-line treatment for patients with metastatic colorectal cancer in China, especially after a recent price drop suggested by the National Healthcare Security Administration. METHODS: A Markov model was developed to in...
Guardat en:
| Publicat a: | BMC Cancer |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7556971/ https://ncbi.nlm.nih.gov/pubmed/33050905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07486-w |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|